open access

Vol 4, No 3 (2003): Practical Diabetology
Original articles (translated)
Published online: 2003-05-22
Get Citation

Long-term renoprotective effects of losartan in diabetic nephropathy. Interaction with ACE insertion/deletion genotype?

Steen Andersen, Lise Tarnow, Francois Cambien, Peter Rossing, Tina R. Juhl, Jaap Deinum, Hans-Henrik Parving
Diabetologia Praktyczna 2003;4(3):211-218.

open access

Vol 4, No 3 (2003): Practical Diabetology
Original articles (translated)
Published online: 2003-05-22

Abstract

INTRODUCTION. Several observational follow-up studies have found that the D allele of the insertion (I)/deletion (D) polymorphism of the ACE gene (ACE/ID) is associated with an increased risk of renal function loss, even during ACE inhibition. Therefore, we investigated the long-term effect of the angiotensin II subtype-1 (AT1) receptor antagonist losartan (100 mg o.d.) on kidney function in II and DD type 1 diabetic patients with diabetic nephropathy.
MATERIAL AND METHODS. A total of 54 hypertensive type 1 diabetic patients with diabetic nephropathy homozygous for the insertion (n = 26) or the deletion (n = 28) allele were included in the study. After a 4-week washout, the patients received losartan (tablet, 100 mg o.d.) and were followed prospectively with a mean follow-up period of 36 months. Patients and investigators were blinded to ACE genotypes. At baseline, after 2 and 4 months and every 6 months thereafter, glomerular filtration rate (GFR), albuminuria, and 24-h blood pressure were determined.
RESULTS. At baseline, GFR, albuminuria, and blood pressure were similar in the two genotype groups, II vs. DD: mean (SD), 86 (22) vs. 88 (24) ml x min–1 × 1.73 m–2; median (interquartile range), 1,134 (598–2,023) vs. 1,451 (893–1,766) mg/24 h; and mean (SD), 156/82 (17/9) vs. 153/80 (17/11) mm Hg, respectively. GFR decreased similarly in both genotype groups, versus DD, respectively (P = 0.4): geometric mean (95% CI), 2.9 (2.0–4.2) vs. 3.4 (2.3–5.1) ml × min–1 x year–1 . Albuminuria and arterial blood pressure were significantly reduced during the study; no differences were noted between groups. During follow-up, albuminuria was decreased by 75% (95% CI 59–85) and 73% (56–83) in the II and DD groups, respectively (P < 0.01 vs. baseline). Mean systolic and diastolic blood pressures were 139/74 mm Hg (14/8) in both genotype groups during the study (P < 0.01 vs. baseline).
CONCLUSIONS. In contrast to previous observational studies with ACE inhibitors, longterm treatment with losartan has similar beneficial renoprotective effects on progression of diabetic nephropathy in hypertensive type 1 diabetic patients with ACE II and DD genotypes.

Abstract

INTRODUCTION. Several observational follow-up studies have found that the D allele of the insertion (I)/deletion (D) polymorphism of the ACE gene (ACE/ID) is associated with an increased risk of renal function loss, even during ACE inhibition. Therefore, we investigated the long-term effect of the angiotensin II subtype-1 (AT1) receptor antagonist losartan (100 mg o.d.) on kidney function in II and DD type 1 diabetic patients with diabetic nephropathy.
MATERIAL AND METHODS. A total of 54 hypertensive type 1 diabetic patients with diabetic nephropathy homozygous for the insertion (n = 26) or the deletion (n = 28) allele were included in the study. After a 4-week washout, the patients received losartan (tablet, 100 mg o.d.) and were followed prospectively with a mean follow-up period of 36 months. Patients and investigators were blinded to ACE genotypes. At baseline, after 2 and 4 months and every 6 months thereafter, glomerular filtration rate (GFR), albuminuria, and 24-h blood pressure were determined.
RESULTS. At baseline, GFR, albuminuria, and blood pressure were similar in the two genotype groups, II vs. DD: mean (SD), 86 (22) vs. 88 (24) ml x min–1 × 1.73 m–2; median (interquartile range), 1,134 (598–2,023) vs. 1,451 (893–1,766) mg/24 h; and mean (SD), 156/82 (17/9) vs. 153/80 (17/11) mm Hg, respectively. GFR decreased similarly in both genotype groups, versus DD, respectively (P = 0.4): geometric mean (95% CI), 2.9 (2.0–4.2) vs. 3.4 (2.3–5.1) ml × min–1 x year–1 . Albuminuria and arterial blood pressure were significantly reduced during the study; no differences were noted between groups. During follow-up, albuminuria was decreased by 75% (95% CI 59–85) and 73% (56–83) in the II and DD groups, respectively (P < 0.01 vs. baseline). Mean systolic and diastolic blood pressures were 139/74 mm Hg (14/8) in both genotype groups during the study (P < 0.01 vs. baseline).
CONCLUSIONS. In contrast to previous observational studies with ACE inhibitors, longterm treatment with losartan has similar beneficial renoprotective effects on progression of diabetic nephropathy in hypertensive type 1 diabetic patients with ACE II and DD genotypes.
Get Citation

Keywords

diabetic nefropathy; ACE polymorphism; losartan

About this article
Title

Long-term renoprotective effects of losartan in diabetic nephropathy. Interaction with ACE insertion/deletion genotype?

Journal

Clinical Diabetology

Issue

Vol 4, No 3 (2003): Practical Diabetology

Pages

211-218

Published online

2003-05-22

Bibliographic record

Diabetologia Praktyczna 2003;4(3):211-218.

Keywords

diabetic nefropathy
ACE polymorphism
losartan

Authors

Steen Andersen
Lise Tarnow
Francois Cambien
Peter Rossing
Tina R. Juhl
Jaap Deinum
Hans-Henrik Parving

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl